Anti-CD20 monoclonal antibody therapy in multiple myeloma. (Q37101674)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Anti-CD20 monoclonal antibody therapy in multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Prashant Kapoor

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Patricia T Greipp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

William G Morice

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Thomas E Witzig

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

Philip R Greipp

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

language of work or name

English

0 references

publication date

3 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Haematology

3 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

135-148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18318769%20AND%20SRC:MED&resulttype=core&format=json

Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell.

3 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Monoclonal antibodies for B-cell lymphomas: rituximab and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Multiple myeloma: the cells of origin--a two-way street

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Investigational treatments for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

CD74 is expressed by multiple myeloma and is a promising target for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Plasma cells: finding new light at the end of B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Monoclonal antibody therapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

FICTION-TSA analysis of the B-cell compartment in myeloma shows no significant expansion of myeloma precursor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Controversies surrounding the clonogenic origin of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Treatment of Waldenström's macroglobulinemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Myeloma stem cell phenotype. Implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Heterogeneity in the multiple myeloma tumor clone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Recombinant immune interferon increases immunoglobulin G Fc receptors on cultured human mononuclear phagocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Identification of the receptor scavenging hemopexin-heme complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Origin and diversification of the clonogenic cell in multiple myeloma: lessons from the immunoglobulin repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Characterization of clonogenic multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Immunotherapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Plasma cell differentiation and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

CD74: a new candidate target for the immunotherapy of B-cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

CD20-Directed Serotherapy in Patients With Multiple Myeloma: Biologic Considerations and Therapeutic Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

The molecular classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X

Initial immunoglobulin M ?flare? after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07024.X